First statin monotherapy to achieve regression of coronary atherosclerosis by angiography in a major clinical study
"The QCA analysis of the ASTEROID study offers us additional, consistent insights into the treatment of patients with coronary artery disease," said Dr. Jean-Claude Tardif, Director of the Montreal Heart Institute Research Centre, and member of the ASTEROID steering committee. "Both QCA and IVUS techniques confirm that the use of rosuvastatin 40 mg can help achieve regression of coronary atherosclerosis, the underlying cause of heart disease."
ASTEROID (A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden) was designed to study the effect of rosuvastatin 40 mg in 507 patients who had undergone coronary angiography and who had evidence of coronary artery disease (CAD). The QCA analysis was a secondary endpoint in the ASTEROID study. Angiograms taken at baseline and at the end of the 2 year study were analysed for changes in the percent diameter stenosis (%DS) and the minimum lumen diameter (MLD) using QCA imaging.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.